New COVID Pill Reduces Risk by 67% — Essential Information for Patients in the US - video Dailymotion

Buzzline

A groundbreaking oral treatment named Xocova has received FDA approval as the inaugural post-exposure pill for COVID-19, demonstrating a 67% reduction in infection risk in a significant Phase 3 clinical trial. This medication is intended for individuals who have been exposed to COVID-19 but have not yet tested positive, providing a proactive intervention strategy as health authorities indicate a potential increase in cases this summer. Medical professionals emphasize the importance of timing — particularly high-risk individuals, such as seniors and those with pre-existing health issues, stand to gain the most from prompt access. Public health officials are closely monitoring case developments as the summer travel season approaches. Pharmacies across the country are set to start offering this medication in the upcoming weeks.

Transcript

00:00A new pill just got FDA approval that could change how Americans handle COVID exposure.

00:05It's called Zocova, and it's the first oral medication approved specifically for post-exposure use.

00:11Meaning you take it after being exposed, before you even test positive.

00:16In a major clinical trial, it cut infection risk by 67%.

00:20That timing matters, because health officials are flagging a possible summer surge risk right now.

00:26Doctors say high-risk Americans, older adults, people with underlying conditions,

00:32stand to benefit the most from early access to this option.

00:36Public health officials are watching case trends closely as summer travel ramps up.

00:41Pharmacies across the country are expected to start stocking it within weeks.

New COVID Pill Reduces Risk by 67% — Essential Information for Patients in the US

Category

Transcript

Comments

Recommended